| | |
p110α
|
P value
|
p110β
|
P value
|
p110δ
|
P value
|
p110γ
|
P value
|
pAKT
|
P value
|
|---|
|
Total no. of patients
|
60
| | | | | | | | | | |
|
Age, years
| | | | | | | | | | |
|
<60 y
|
36
|
12 (33.3)
|
0.037
|
10 (27.8)
|
0.639
|
12 (33.3)
|
0.068
|
7 (19.4)
|
1.000
|
7 (19)
|
0.293
|
|
≥60 y
|
24
|
4 (16.7)
| |
5 (20.8)
| |
3 (12.5)
| |
4 (16.7)
| |
2 (8.3)
| |
|
Sex
| | | | | | | | | | | |
|
Male
|
39
|
7 (17.9)
|
0.153
|
9 (23.1)
|
0.762
|
11 (28.2)
|
0.435
|
7 (17.9)
|
1.000
|
7 (17.9)
|
0.473
|
|
Female
|
21
|
9 (42.9)
| |
6 (28.6)
| |
4 (19.0)
| |
4 (19.0)
| |
2 (9.5)
| |
|
Primary site
| | | | | | | | | | |
|
node
|
54
|
14 (25.9)
|
0.653
|
14 (25.9)
|
1.000
|
14 (25.9)
|
1.000
|
8 (14.8)
|
0.069
|
8 (14.8)
|
1.000
|
|
Perpheral node
|
6
|
2 (33.3)
| |
1 (26.7)
| |
1 (16.7)
| |
3 (50.0)
| |
1 (16.6)
| |
|
B symptoms
| | | | | | | | | | |
|
Absence
|
37
|
10 (27.0)
|
0.936
|
10 (27.0)
|
0.764
|
11 (29.7)
|
0.283
|
6 (16.2)
|
0.734
|
4 (10.8)
|
0.284
|
|
Presence
|
23
|
6 (26.1)
| |
5 (21.7)
| |
4 (17.4)
| |
5 (21.7)
| |
5 (21.7)
| |
|
Bulky disease
| | | | | | | | | | |
|
<10 cm
|
47
|
11 (23.4)
|
1.000
|
13 (27.7)
|
0.561
|
12 (25.5)
|
1.000
|
8 (17.0)
|
0.552
|
7 (14.9)
|
1.000
|
|
≥10 cm
|
4
|
1 (25.0)
| |
1 (0)
| |
1 (25.0)
| |
1 (25.0)
| |
0 (0)
| |
|
Performance status
| | | | | | | | | |
|
ECOG 0-1
|
50
|
13 (26.0)
|
1.000
|
13 (26.0)
|
0.965
|
12 (24.0)
|
1.000
|
9 (18.0)
|
0.571
|
8 (16)
|
1.000
|
|
ECOG 2-4
|
4
|
1 (25.0)
| |
1 (25.0)
| |
1 (25.0)
| |
1 (25.0)
| |
0 (0)
| |
|
LDH
| | | | | | | | | | | |
|
<2*insitutioal ULN
|
30
|
9 (30.0)
|
0.445
|
11 (36.7)
|
0.133
|
9 (30.0)
|
0.445
|
7 (23.3)
|
0.483
|
6 (20)
|
0.277
|
|
>2*insitutioal ULN
|
24
|
5 (20.8)
| |
4 (16.7)
| |
5 (20.8)
| |
3 (12.5)
| |
2 (8.3)
| |
|
Extranodal site
| | | | | | | | | | |
|
≤1
|
50
|
13 (26.0)
|
1.000
|
14 (28.0)
|
1.000
|
13 (26.0)
|
1.000
|
9 (18.0)
|
0.571
|
8 (16)
|
1.000
|
|
>1
|
4
|
1 (25.0)
| |
1 (25.0)
| |
1 (25.0)
| |
1 (25.0)
| |
0 (0)
| |
|
Stage
| | | | | | | | | | | |
|
I/II
|
29
|
5 (17.2)
|
0.077
|
8 (27.6)
|
0.904
|
10 (34.5)
|
0.168
|
4 (13.8)
|
0.307
|
4 (13.8)
|
1.000
|
|
III/IV
|
23
|
9 (39.1)
| |
6 (26.1)
| |
4 (17.4)
| |
6 (26.1)
| |
4 (17.4)
| |
|
IPI
| | | | | | | | | | | |
|
0-1
|
30
|
10 (33.3)
|
0.142
|
11 (36.7)
|
0.087
|
11 (36.7)
|
0.037
|
5 (16.7)
|
1.000
|
6 (20)
|
0.269
|
|
2-5
|
25
|
4 (16.0)
| |
4 (16.0)
| |
3 (12.0)
| |
5 (20.0)
| |
2 (8)
| |
|
Pathological type
| | | | | | | | | |
|
GCB
|
26
|
4 (15.4)
|
0.084
|
6 (23.1)
|
0.764
|
4 (15.4)
|
0.133
|
3 (11.5)
|
0.320
|
4 (15.4)
|
1.000
|
|
non-GCB
|
34
|
12 (35.3)
| |
9 (26.5)
| |
11 (32.4)
| |
8 (23.5)
| |
5 (14.7)
| |
-
DLBCL diffuse large B-cell lymphoma, GCB germinal center B cell, IPI international prognostic index, LDH lactate dehydrogenase.
